COVID-19 Coagulopathy

This title is printed to order. This book may have been self-published. If so, we cannot guarantee the quality of the content. In the main most books will have gone through the editing process however some may not. We therefore suggest that you be aware of this before ordering this book. If in doubt check either the author or publisher’s details as we are unable to accept any returns unless they are faulty. Please contact us if you have any questions.

This Special Issue aims to dismantle the mechanisms and molecular pathways underlying COVID-19-induced coagulopathy, and present the current advances made possible by our colleagues' research. The 15 published paper contributions encompassed molecular recruitment and binding, enzymatic dynamics and hemostasis disorders, as well as imagistic high-risk identifiers among the coronary disease population affected by the virus, the connection between psychiatric patients also affected and the thrombosis risk of their antipsychotic therapy, and complications in pediatric patients, along with those with primary and secondary immune disorders.

As underlined by the published papers, this Special Issue has brought important contributions in understanding the root mechanisms of SARS-CoV-2-induced coagulopathy, defining diagnostic and prognostic biomarkers, and establishing the role of anti-coagulant and anti-thrombotic therapies which are the most effective for this complex disease.

We are pleased to acknowledge that researchers from various fields came together in an effort to provide necessary data about the many forms and manifestations of the coagulations disorders challenging the medical community since the early stages of the pandemic. These data can represent a basis for further studies and a fertile ground for later developments.